Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering priced at-the-market under Nasdaq rules for 12,325,000 common shares. Each common …
Philadelphia & Vancouver, British Columbia – September 11, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 12,325,000 common shares (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), priced …
• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor • OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature • Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population • No drug related discontinuations …
• BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancer • The meeting provides a clear path towards filing an IND and conducting a Phase 1/2 study of Bria-PROS+™ PHILADELPHIA, PA and VANCOUVER, British Columbia, September 10, 2024— BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) …
PHILADELPHIA, PA and VANCOUVER, British Columbia, September 9, 2024— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX. …
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient – quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously reported Heavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC) therapy and continues to receive BriaCell treatment PHILADELPHIA …
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients Therapy well-tolerated with no Bria-IMT™ related discontinuations Clinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancer Superiority of selected Phase …
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, …
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform …
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases Median progression free survival (PFS) of 4.1 months in ADC resistant patients – double the PFS of patients in similar studies 1,2, 3 Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease …